Clinical Significance of Substaging and HER2 Expression in Papillary Nonmuscle Invasive Urothelial Cancers of the Urinary Bladder.
10.3346/jkms.2015.30.8.1068
- Author:
So Dug LIM
1
;
Yong Mee CHO
;
Gyu Seog CHOI
;
Hyung Kyu PARK
;
Sung Hyun PAICK
;
Wook Youn KIM
;
Soo Nyung KIM
;
Ghilsuk YOON
Author Information
1. Department of Pathology, Konkuk University Medical Center, Konkuk University School of Medicine, Seoul, Korea.
- Publication Type:Original Article ; Research Support, Non-U.S. Gov't
- Keywords:
Bladder Cancer;
Cancer Staging;
HER2 Gene;
Immunohistochemistry;
In Situ Hybridization
- MeSH:
Adult;
Aged;
Aged, 80 and over;
Biomarkers, Tumor/*metabolism;
Carcinoma, Papillary/*metabolism/*pathology;
Carcinoma, Transitional Cell/metabolism/pathology;
Female;
Humans;
Male;
Middle Aged;
Neoplasm Staging;
Receptor, ErbB-2/*metabolism;
Reproducibility of Results;
Sensitivity and Specificity;
Urinary Bladder Neoplasms/*metabolism/*pathology;
Young Adult
- From:Journal of Korean Medical Science
2015;30(8):1068-1077
- CountryRepublic of Korea
- Language:English
-
Abstract:
The study aimed to verify the prognostic utility, therapeutic application and clinical benefits of tumor substaging and HER2 status in papillary non-muscle invasive bladder cancer (NMIBC). Select NMIBC transurethral resection specimens from 141 patients were used to construct tissue microarrays for assessing the substaging, HER2 protein expression by immunohistochemistry (HER2-IHC) and gene amplification by dual-color silver in situ hybridization (HER2-SISH). Substages were identified by the differing depth of tumor invasion (pTa / pT1a / pT1b / pT1c). HER2 protein expression was semiquantitatively analyzed and grouped into negative (score 0, 1+) and positive (score 2+, 3+). Other clinicopathological variables were also investigated. For NMIBC, HER2-IHC and HER2-SISH showed positive results in 6/141 (4.3%) and 4/141 (2.8%) respectively, which correlated well with tumor substaging. In multivariate analysis, substaging, HER2-IHC, and HER2-SISH were found to be independent predictors of progression-free survival (P < 0.001, P < 0.001, P = 0.031). HER2-IHC was the sole independent predictor of recurrent free survival in NMIBC (P = 0.017). It is suggested that tumor substaging and HER2 status are independent predictive markers for tumor progression or recurrence, and thus could be included in diagnostic and therapeutic management for NMIBC.
